| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2021: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
Using FLT3-ITD AML cell lines, we confirmed the inhibitory effect of the PRMT5 inhibitor on AML cell proliferation. DUSP4 is a known enzyme that dephosphorylates ERK1/2, which is important for cell proliferation. The PRMT5 inhibiter increased DUSP4 expression.
We showed synergistically inhibited the proliferation of FLT3-ITD AML cells with the combination therapy of FLT3 inhibitor and PRMT5 inhibitor. This indicates that combination therapy with the PRMT5 inhibitor and the FLT3 inhibitor may be effective in FLT3-ITD AML
|
